Description: Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.
Home Page: www.kerostx.com
KROS Technical Analysis
99 Hayden Avenue
Lexington,
MA
02421
United States
Phone:
617 314 6297
Officers
| Name | Title |
|---|---|
| Dr. Jasbir S. Seehra Ph.D. | Pres, CEO, Treasurer, & Director |
| Mr. Keith C. Regnante MBA | Chief Financial Officer |
| Dr. Jennifer Lachey Ph.D. | Chief Scientific Officer |
| Mr. Christopher Rovaldi M.Sc. | Chief Operating Officer |
| Ms. Esther Cho J.D. | Head of Legal & Corp. Sec. |
| Ms. Robin Wagner | VP of HR |
| Dr. Simon Cooper MBBS | Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.7412 |
| Price-to-Sales TTM: | 68.4176 |
| IPO Date: | 2020-04-08 |
| Fiscal Year End: | December |
| Full Time Employees: | 104 |